Skip to main content
Skip to main content
MD logo

Pediatrix Medical Group, Inc. (MD)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Pediatrix Medical Group, Inc. (MD) trades at $20.98 with AI Score 49/100 (Weak). Pediatrix Medical Group, Inc. provides specialized healthcare services for newborns, expectant mothers, and children across the United States and Puerto Rico. Market cap: $1.80B, Sector: Healthcare.

Last analyzed: Feb 9, 2026
Pediatrix Medical Group, Inc. provides specialized healthcare services for newborns, expectant mothers, and children across the United States and Puerto Rico. The company operates a network of physicians focused on neonatal, maternal-fetal, and pediatric cardiology care.
49/100 AI Score Target $20.67 (-1.5%) MCap $1.80B Vol 558.2K

Pediatrix Medical Group, Inc. (MD) Healthcare & Pipeline Overview

CEOKasandra H. Rossi
Employees4120
HeadquartersSunrise, FL, US
IPO Year1995

Pediatrix Medical Group offers specialized care for newborns, mothers, and children, leveraging a comprehensive network of physicians and a focus on high-growth pediatric subspecialties. With a P/E of 11.00 and a solid 8.4% profit margin, MD presents a compelling value proposition in the healthcare sector.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Feb 9, 2026

Investment Thesis

Pediatrix Medical Group presents a notable research candidate due to its specialized focus and established market presence. With a P/E ratio of 11.00 and a profit margin of 8.4%, the company demonstrates financial stability and growth potential. Key value drivers include the increasing demand for specialized pediatric and maternal care, driven by advancements in medical technology and a growing awareness of complex health issues in newborns and children. Growth catalysts include expanding service offerings within existing markets and strategic acquisitions to broaden geographic reach. The company's beta of 0.78 suggests lower volatility compared to the broader market, making it a noteworthy option for risk-averse investors. Continued focus on operational efficiency and strategic partnerships should further enhance profitability and shareholder value.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $1.79 billion, reflecting substantial investor confidence in the company's market position.
  • P/E ratio of 11.00, indicating a potentially undervalued stock compared to its earnings.
  • Profit margin of 8.4%, demonstrating efficient operations and profitability in the healthcare services sector.
  • Gross margin of 25.8%, showcasing the company's ability to manage costs effectively.
  • Beta of 0.78, suggesting lower volatility compared to the broader market, appealing to risk-averse investors.

Competitors & Peers

Strengths

  • Specialized expertise in high-demand pediatric and maternal care services.
  • Extensive network of physicians and hospital partnerships.
  • Strong reputation for quality care and positive patient outcomes.
  • Established market presence and brand recognition.

Weaknesses

  • Dependence on reimbursement rates and regulatory policies.
  • Potential for physician turnover and staffing challenges.
  • Geographic concentration in certain markets.
  • Exposure to medical malpractice claims and litigation.

Catalysts

  • Expansion of telehealth services to improve access to care and increase revenue.
  • Strategic acquisitions of smaller practices to broaden geographic presence and service offerings.
  • Development and launch of specialized pediatric programs to attract more patients.
  • Enhancement of maternal-fetal medicine services to address growing demand for prenatal care.

Risks

  • Changes in healthcare regulations and reimbursement policies could negatively impact revenue.
  • Increased competition from other healthcare providers could erode market share.
  • Economic downturns could affect patient volumes and healthcare spending.
  • Medical malpractice claims and litigation could result in significant financial losses.
  • Physician turnover and staffing challenges could disrupt operations and impact quality of care.

Growth Opportunities

  • Expansion of Telehealth Services: Pediatrix can leverage telehealth to extend its reach to underserved areas and improve access to specialized care. The telehealth market is projected to reach $400 billion by 2028, offering a significant growth opportunity. By investing in telehealth infrastructure and virtual care programs, Pediatrix can enhance patient engagement and improve outcomes, driving revenue growth and market share.
  • Strategic Acquisitions and Partnerships: Pediatrix can pursue strategic acquisitions of smaller pediatric practices and partnerships with hospitals to expand its network and service offerings. This approach allows the company to enter new markets quickly and efficiently, leveraging existing infrastructure and expertise. Targeted acquisitions in high-growth areas can significantly boost revenue and profitability within the next 3-5 years.
  • Development of Specialized Pediatric Programs: Focusing on developing specialized programs for specific pediatric conditions, such as pediatric cardiology and neurology, can attract more patients and increase revenue. These programs can be marketed to hospitals and healthcare systems, creating a recurring revenue stream. The market for specialized pediatric care is growing, driven by advancements in medical technology and increasing awareness of complex health issues.
  • Enhancement of Maternal-Fetal Medicine Services: Expanding maternal-fetal medicine services to address the growing demand for prenatal care and high-risk pregnancy management can drive significant growth. This includes offering advanced diagnostic testing, genetic counseling, and specialized care for expectant mothers with complex medical conditions. The maternal-fetal medicine market is expected to grow at a CAGR of 6% over the next five years, presenting a substantial opportunity for Pediatrix.
  • Investment in Data Analytics and AI: Utilizing data analytics and artificial intelligence to improve clinical outcomes, optimize operations, and personalize patient care can provide a competitive advantage. By analyzing patient data, Pediatrix can identify trends, predict potential health issues, and develop targeted interventions. This can lead to improved patient satisfaction, reduced costs, and increased efficiency, driving long-term growth and profitability.

Opportunities

  • Expansion of telehealth services to reach underserved areas.
  • Strategic acquisitions and partnerships to broaden geographic reach.
  • Development of specialized pediatric programs for specific conditions.
  • Enhancement of maternal-fetal medicine services to address growing demand.

Threats

  • Changes in healthcare regulations and reimbursement policies.
  • Increased competition from other healthcare providers.
  • Economic downturns affecting patient volumes and healthcare spending.
  • Potential for medical malpractice claims and litigation.

Competitive Advantages

  • Specialized Expertise: Deep expertise in neonatal, maternal-fetal, and pediatric cardiology care creates a barrier to entry.
  • Extensive Network: A large network of physicians and hospital partnerships provides a competitive advantage.
  • Reputation: A strong reputation for quality care and positive patient outcomes enhances brand loyalty.
  • Scale: The company's size and scale allow for economies of scale and efficient operations.

About MD

Founded in 1979 and headquartered in Sunrise, Florida, Pediatrix Medical Group, Inc. has evolved into a leading provider of specialized medical care. Originally known as MEDNAX, Inc., the company rebranded in July 2022 to better reflect its core focus on pediatric and maternal health. Pediatrix operates across the United States and Puerto Rico, offering a comprehensive suite of services including neonatal care, maternal-fetal care, pediatric cardiology, and other pediatric subspecialty services. Their neonatal care focuses on premature babies and those with complications, providing clinical care within hospital units. Maternal-fetal care includes inpatient and office-based services for expectant mothers and unborn babies. Pediatric cardiology addresses congenital heart defects and acquired heart disease. The company also offers specialized services in pediatric intensive care, hospitalist care, surgery, ophthalmology, and ENT. As of February 17, 2022, Pediatrix operated a network of approximately 2,700 physicians, solidifying its position as a key player in specialized pediatric and maternal healthcare.

What They Do

  • Provides clinical care to premature babies and newborns with complications.
  • Offers inpatient and office-based care to expectant mothers and unborn babies.
  • Delivers pediatric cardiology care for congenital heart defects and acquired heart disease.
  • Provides specialized cardiac care to fetuses, neonates, and pediatric patients.
  • Offers pediatric subspecialty care through intensivists, hospitalists, surgeons, and ophthalmologists.
  • Supports hospitals in pediatric emergency rooms, labor and delivery areas, and nursery departments.
  • Operates a network of approximately 2,700 physicians across the United States and Puerto Rico.

Business Model

  • Generates revenue through providing specialized medical care services.
  • Contracts with hospitals and healthcare systems to provide physician staffing and management.
  • Receives payments from insurance companies, government programs, and patients for services rendered.
  • Expands service offerings and geographic reach through strategic acquisitions and partnerships.

Industry Context

Pediatrix Medical Group operates within the medical care facilities industry, which is experiencing steady growth driven by increasing demand for specialized healthcare services. The market is characterized by a mix of large national providers and smaller regional players. Key trends include the growing prevalence of chronic conditions in children and the increasing need for specialized neonatal and maternal-fetal care. The competitive landscape includes companies like Acadia Healthcare (ACHC) and American Addiction Centers (ADUS), which focus on behavioral health, while Pediatrix specializes in pediatric and maternal care. The industry is also influenced by regulatory changes and reimbursement policies, requiring companies to adapt to evolving healthcare standards.

Key Customers

  • Hospitals and healthcare systems seeking specialized pediatric and maternal care services.
  • Expectant mothers requiring maternal-fetal medicine services.
  • Newborns and children needing neonatal and pediatric subspecialty care.
  • Insurance companies and government programs covering healthcare costs.
AI Confidence: 72% Updated: Feb 9, 2026

Financials

Chart & Info

Pediatrix Medical Group, Inc. (MD) stock price: $20.98 (-0.21, -0.99%)

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MD.

Price Targets

Consensus target: $20.67

MoonshotScore

49/100

What does this score mean?

The MoonshotScore rates MD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Pediatrix Medical Group, Inc. Healthcare Stock: Key Questions Answered

What does Pediatrix Medical Group, Inc. do?

Pediatrix Medical Group, Inc. specializes in providing medical care services for newborns, expectant mothers, and children. The company operates a network of physicians who offer neonatal care, maternal-fetal care, pediatric cardiology, and other pediatric subspecialty services. Pediatrix partners with hospitals and healthcare systems to provide physician staffing and management, ensuring high-quality care in pediatric emergency rooms, labor and delivery areas, and nursery departments. Their focus on specialized care and extensive network of physicians positions them as a key player in the healthcare industry.

Is MD stock worth researching?

MD stock presents a mixed picture for potential investors. The company's P/E ratio of 11.00 suggests it may be undervalued compared to its earnings, and its profit margin of 8.4% indicates financial stability. However, potential investors may want to evaluate the risks associated with healthcare regulations, competition, and potential economic downturns. Growth opportunities in telehealth and strategic acquisitions could drive future growth, but careful analysis of these factors is essential before making an investment decision.

What are the main risks for MD?

Pediatrix Medical Group faces several risks, including changes in healthcare regulations and reimbursement policies, which could negatively impact revenue. Increased competition from other healthcare providers could erode market share, and economic downturns could affect patient volumes and healthcare spending. Additionally, the company is exposed to medical malpractice claims and litigation, which could result in significant financial losses. Physician turnover and staffing challenges could also disrupt operations and impact the quality of care provided.

What are the key factors to evaluate for MD?

Pediatrix Medical Group, Inc. (MD) currently holds an AI score of 49/100, indicating low score. The stock trades at a P/E of 10.7x, below the S&P 500 average (~20-25x), potentially signaling value. Analysts target $20.67 (-1% from $20.98). Key strength: Specialized expertise in high-demand pediatric and maternal care services. Primary risk to monitor: Changes in healthcare regulations and reimbursement policies could negatively impact revenue. This is not financial advice.

How frequently does MD data refresh on this page?

MD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven MD's recent stock price performance?

Recent price movement in Pediatrix Medical Group, Inc. (MD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $20.67 implies 1% downside from here. Notable catalyst: Specialized expertise in high-demand pediatric and maternal care services. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider MD overvalued or undervalued right now?

Determining whether Pediatrix Medical Group, Inc. (MD) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 10.7. Analysts target $20.67 (-1% from current price), suggesting analysts see the stock near fair value. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying MD?

Before investing in Pediatrix Medical Group, Inc. (MD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Stock data pending update.
  • Information is based on available data as of February 9, 2026.
Data Sources

Popular Stocks